Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Total Current Liabilities data on file, last reported at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 23.73% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (up 23.73% YoY), and the FY2025 full-year result was $13.1 million, up 54.28% from the prior year.
• Total Current Liabilities retreated to $10.2 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $13.1 million in Q4 2025 to a low of $5.5 million in Q1 2022.
• A 5-year average of $9.3 million and a median of $9.0 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 116.98% in 2022 and sank 47.3% in 2024, its largest moves.
• Tracing DSGN's Total Current Liabilities over 5 years: stood at $10.8 million in 2022, then decreased by 10.71% to $9.6 million in 2023, then retreated by 12.06% to $8.5 million in 2024, then soared by 54.28% to $13.1 million in 2025, then declined by 21.95% to $10.2 million in 2026.
• Business Quant data shows DSGN's Total Current Liabilities at $10.2 million in Q1 2026, $13.1 million in Q4 2025, and $11.2 million in Q3 2025.